-

Fresenius Kabi Receives Pharmacy Strategic Programs Excellence Award From Vizient®

The Pharmacy Strategic Programs Excellence Award recognizes superior service, support, reliability, ethics, and integrity.

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, was awarded the 2026 Pharmacy Strategic Programs Excellence Award by Vizient®, the nation’s largest provider-driven healthcare performance improvement company.

Fresenius Kabi, part of the global healthcare company Fresenius, was awarded the 2026 Pharmacy Strategic Programs Excellence Award by Vizient®, the nation’s largest provider-driven healthcare performance improvement company.

Share

The award recognizes Fresenius Kabi’s efforts to successfully empower Vizient’s provider clients to optimize costs, quality, and market performance while strengthening the healthcare supply chain.

The honor was announced September 22, 2026, at an awards ceremony at the Vizient Connections Summit in Las Vegas. Vizient’s diverse client base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers.

“Congratulations to Fresenius Kabi on receiving the 2026 Pharmacy Strategic Programs Excellence Award,” said Simrit Sandhu, president, spend management, Vizient. “This recognition reflects the company’s commitment to supporting Vizient clients as they work to optimize pharmacy performance, manage costs and strengthen the healthcare supply chain.”

“We’re honored to be recognized by Vizient for our service record with their providers,” said Arun Verma, president, Fresenius Kabi Region U.S. and member of the Executive Leadership Team, Fresenius Kabi AG. “Our goal is always to assure a long-term, sustainable drug supply so providers can provide the highest quality of care.”

About Fresenius Kabi

Fresenius Kabi is part of the global healthcare company Fresenius and specializes in lifesaving medicines, medical technologies, and services for critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi’s broad portfolio enables access to high-quality products across emergency medicine, surgery, oncology, intensive care, and at home – reaching around 450 million patients each year.

Through complementary business areas, Fresenius Kabi offers highly complex biopharmaceuticals for the treatment of cancer, autoimmune and endocrine diseases; leading enteral, parenteral and homecare solutions within medical nutrition; innovative medical technology including infusion pumps, cell and gene therapy devices, disposables and blood collection systems; and intravenous generic drugs and fluids that are vital to the work of healthcare providers globally.

For more information, please visit www.fresenius-kabi.com.

About Fresenius

Fresenius (XFRA: FRE, OTC: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.

Contacts

Media contact
Matt Kuhn (847) 220-3033
matt.kuhn@fresenius-kabi.com

Industry:

Fresenius Kabi

Release Versions
English
Hashtags
#CommittedToLife

Contacts

Media contact
Matt Kuhn (847) 220-3033
matt.kuhn@fresenius-kabi.com

Social Media Profiles
Fresenius Kabi USA
Fresenius Kabi USA on YouTube
More News From Fresenius Kabi

Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals

LAKE ZURICH, Ill. & BETHESDA, Md.--(BUSINESS WIRE)--Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) announced today the launch of the 21st annual Blood Collectors Week, taking place September 6–12, 2026. The annual recognition week celebrates the blood collection professionals whose expertise and dedication help ensure patients across the country have access to safe, high-quality blood and blood components. Blood Collectors Week honors the essential pro...

Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, a global healthcare company part of the Fresenius Group, specializing in lifesaving therapies and technologies, today announced the U.S. launch of the FDA‑approved generic Sugammadex Injection. Exclusivity for the branded medicine Bridion® (Merck) expired in July 2026. Fresenius Kabi offers operating room clinicians Sugammadex in a Simplist® ready-to-administer prefilled syringe. Simplist® single-dose, prefilled syringes require no assembly at...

Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More se...
Back to Newsroom